Billionaire Profile
M
Global Rank
#334

Image: Royal Zoological Society of Ireland | Public domain | via Wikimedia Commons

Murali Divi & family

CEO, Pharmaceuticals
INDIA
Real-Time Net Worth
$9.926B
Estimated based on Pharmaceuticals stock value as of March 6, 2026
+1.67% (24h)
Age
74
Source
Pharmaceuticals
Industry
Healthcare
Citizenship
INDIA

Biography

Dr. Murali Krishna Prasad Divi, the founder of Divi's Laboratories, is a prominent Indian billionaire in the pharmaceutical industry. Born in a small village in Andhra Pradesh, he overcame early academic challenges and financial struggles to build a global pharmaceutical company. His career began with experience in the US and later, he returned to India to start Divi's Laboratories in 1990. Today, the company is a leading manufacturer of active pharmaceutical ingredients (APIs) and is recognized as one of the top pharmaceutical companies in India. Divi's net worth reflects his successful career and his company's impact on the healthcare sector.

Fact Checked
Verified by Editorial Team
Live Data
Updated 3/6/2026

Wealth Over Time

Portfolio Holdings

In-Depth Profile

Early Life

Murali Krishna Prasad Divi was born in a small village in Andhra Pradesh. He came from a large family with humble beginnings, facing financial challenges. Despite these struggles, Divi was determined to pursue higher education, despite facing setbacks in his early schooling. He studied in Machilipatnam and later attended MIT, Manipal, where he started to realize the value of hard work.

Rise to Success

After briefly working in the US in the pharmaceutical industry, Divi returned to India and started Divi's Laboratories in 1990. The company initially focused on developing commercial processes for manufacturing APIs and intermediates. Divi's Labs quickly grew to become a major player in the pharmaceutical industry. Divi's Laboratories went public with its initial public offering (IPO) on February 17, 2003. Today, Divi's Laboratories is recognized as one of the top pharmaceutical companies in India.

Key Business Strategies

Divi's Laboratories focuses on manufacturing Generic APIs, Intermediates, and Nutraceutical Ingredients, and offers Custom Synthesis of APIs to Big Pharma. The company has invested in research and development with multiple R&D centers. Divi's Laboratories' revenue reached $1.1 billion in 2025, with exports accounting for nearly 90% of its revenue.

Philanthropy

Information regarding Murali Divi's specific philanthropic initiatives and amounts could not be found in the search results.

Career Milestones

1990

Founded Divi's Laboratories

Founded Divi's Laboratories as a drug research firm.

1994

Expanded into API Manufacturing

Divi's Research Centre changed its name to Divi's Laboratories Limited to enter the API and intermediates manufacturing industry.

2003

IPO

The company went public with its initial public offering (IPO) on 17 February 2003.

2020

CEO

Satchandra Kiran Divi is the current CEO.

Philanthropy & Social Impact

N/A

N/A

Undisclosed

No specific information found regarding philanthropy.

Business Philosophy & Leadership

Notable Quotes

""My main business is running farms and growing orchards running pharmaceutical companies is my hobby.""

Leadership Principles

Focus on Quality

Meeting or exceeding the quality levels set by the customer.

Investment in R&D

Developing commercially viable processes.

Controversies & Challenges

2017

FDA Restrictions

The US FDA imposed restrictions on one of its factories, which were resolved within six months.